Plain-English translation of NCT03830320 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Atrial Fibrillation research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
Researchers are testing a new imaging tool called to see if it can safely and accurately detect blood clots in the heart and body. The medication is injected before a special PET scan (a type of imaging that shows where blood clots may be forming). This trial will first make sure the scan is safe in healthy people, then test whether it works well for people with atrial fibrillation, COVID-19, cancer, or suspected blood clots elsewhere in the body.
Currently, doctors use ultrasound and other tests to find blood clots, but these methods have limitations and are not always accurate. This trial aims to see if this new imaging approach could provide doctors with a better, more precise way to spot dangerous blood clots early—which is especially important for people at high risk.
You likely qualify if…
You likely don't qualify if…
If you are a healthy volunteer, you will receive an injection of the imaging medication and undergo one PET scan, plus blood tests and heart rhythm tests before and after the scan. If you have atrial fibrillation, COVID-19, cancer, or a suspected blood clot, you will also receive the injection and have a PET scan, usually scheduled around your existing medical care (such as an ultrasound or upcoming heart procedure). Most visits involve one imaging session, though healthy volunteers and some patient groups will have additional blood draws to track how the medication moves through your body.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States